Information Provided By:
Fly News Breaks for January 15, 2020
BSX
Jan 15, 2020 | 07:37 EDT
Cowen analyst Joshua Jennings thinks the pullback in Boston Scientific shares in response to Q4 sales results and its second quarterly miss this year, is an overdone. He believes investors should have confidence in the outlook for 2020 and beyond, especially given its lineup of new product launches. Jennings said he would use the weakness as a buying opportunity and he reiterated his Outperform rating and $52 price target on Boston Scientific shares.
News For BSX From the Last 2 Days
BSX
Apr 25, 2024 | 08:24 EDT
Evercore ISI analyst Vijay Kumar raised the firm's price target on Boston Scientific to $78 from $72 and keeps an Outperform rating on the shares as the firm said the company reported "solid results and there wasn't much to pick on." While EP franchise acceleration driven by Farapulse PFA launch "is generally well known" by the Street, the firm says it doesn't think "anyone expected ~86% US growth and ~72% International growth."
BSX
Apr 25, 2024 | 06:29 EDT
Baird analyst David Rescott raised the firm's price target on Boston Scientific to $84 from $79 and keeps an Outperform rating on the shares. The firm noted its 1Q24 revenue/adjusted EPS beat was the biggest over the past several years and one of the most compelling in diversified LGCP MedTech.
BSX
Apr 24, 2024 | 13:53 EDT
Stifel raised the firm's price target on Boston Scientific to $83 from $70 and keeps a Buy rating on the shares. The firm said the company delivered "solid" Q1 outperformance, underpinned by "important" new product launches. Looking ahead to 2024 and beyond, Stifel believes Boston Scientific could continue outperforming their Loan Repayment Program and the firm's projections.
BSX
Apr 24, 2024 | 08:50 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here